Literature DB >> 26735398

Take two: Combining immunotherapy with epigenetic drugs to tackle cancer.

Karen Weintraub.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26735398     DOI: 10.1038/nm0116-8

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

Authors:  David Roulois; Helen Loo Yau; Rajat Singhania; Yadong Wang; Arnavaz Danesh; Shu Yi Shen; Han Han; Gangning Liang; Peter A Jones; Trevor J Pugh; Catherine O'Brien; Daniel D De Carvalho
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

2.  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Authors:  Katherine B Chiappinelli; Pamela L Strissel; Alexis Desrichard; Huili Li; Christine Henke; Benjamin Akman; Alexander Hein; Neal S Rote; Leslie M Cope; Alexandra Snyder; Vladimir Makarov; Sadna Budhu; Sadna Buhu; Dennis J Slamon; Jedd D Wolchok; Drew M Pardoll; Matthias W Beckmann; Cynthia A Zahnow; Taha Merghoub; Taha Mergoub; Timothy A Chan; Stephen B Baylin; Reiner Strick
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

3.  Targeted p16(Ink4a) epimutation causes tumorigenesis and reduces survival in mice.

Authors:  Da-Hai Yu; Robert A Waterland; Pumin Zhang; Deborah Schady; Miao-Hsueh Chen; Yongtao Guan; Manasi Gadkari; Lanlan Shen
Journal:  J Clin Invest       Date:  2014-07-25       Impact factor: 14.808

4.  Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.

Authors:  Jean-Pierre Issa; Guillermo Garcia-Manero; Xuelin Huang; Jorge Cortes; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Mark Brandt; Sherry Pierce; Hagop M Kantarjian
Journal:  Cancer       Date:  2014-10-21       Impact factor: 6.860

5.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.

Authors:  KiBem Kim; Andrew D Skora; Zhaobo Li; Qiang Liu; Ada J Tam; Richard L Blosser; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

  7 in total
  26 in total

1.  Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.

Authors:  Jhanelle E Gray; Amer A Beg; Andreas Saltos; Tawee Tanvetyanon; Eric B Haura; Ben Creelan; Scott J Antonia; Michael Shafique; Hong Zheng; Wenjie Dai; James J Saller; Zhihua Chen; Nishan Tchekmedyian; Kristen Goas; Ram Thapa; Theresa A Boyle; Dung-Tsa Chen
Journal:  Clin Cancer Res       Date:  2019-08-13       Impact factor: 12.531

2.  The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma.

Authors:  Shi-Yi Wu; Zhao-Yu Xie; Lu-Yu Yan; Xiao-Fang Liu; Yue Zhang; Da-An Wang; Jie Dong; Hong-Tao Sun
Journal:  BMC Immunol       Date:  2022-06-04       Impact factor: 3.594

Review 3.  Endogenous retroviruses in the origins and treatment of cancer.

Authors:  Natasha Jansz; Geoffrey J Faulkner
Journal:  Genome Biol       Date:  2021-05-10       Impact factor: 13.583

Review 4.  Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors.

Authors:  Nada K Sedky; Alyaa A Hamdan; Salma Emad; Aya L Allam; Mohamed Ali; Mai F Tolba
Journal:  Clin Transl Oncol       Date:  2022-01-23       Impact factor: 3.405

5.  Human endogenous retroviruses and cancer.

Authors:  María Gonzalez-Cao; Paola Iduma; Niki Karachaliou; Mariacarmela Santarpia; Julià Blanco; Rafael Rosell
Journal:  Cancer Biol Med       Date:  2016-12       Impact factor: 4.248

Review 6.  Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma.

Authors:  Mankgopo M Kgatle; Mashiko Setshedi; Henry N Hairwadzi
Journal:  Biomed Res Int       Date:  2016-12-26       Impact factor: 3.411

7.  The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.

Authors:  Hongjuan Zhao; Shoucheng Ning; Rosalie Nolley; Jan Scicinski; Bryan Oronsky; Susan J Knox; Donna M Peehl
Journal:  Clin Epigenetics       Date:  2017-01-19       Impact factor: 6.551

8.  LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.

Authors:  T Boulding; R D McCuaig; A Tan; K Hardy; F Wu; J Dunn; M Kalimutho; C R Sutton; J K Forwood; A G Bert; G J Goodall; L Malik; D Yip; J E Dahlstrom; A Zafar; K K Khanna; S Rao
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

Review 9.  Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.

Authors:  Romain Cohen; Benoît Rousseau; Joana Vidal; Raphaël Colle; Luis A Diaz; Thierry André
Journal:  Target Oncol       Date:  2020-02       Impact factor: 4.864

10.  Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.

Authors:  Cristina Riccadonna; Céline Yacoub Maroun; Romain Vuillefroy de Silly; Margaux Boehler; Marta Calvo Tardón; Simone Jueliger; Pietro Taverna; Leticia Barba; Eliana Marinari; Serena Pellegatta; Esen Yonca Bassoy; Denis Martinvalet; Pierre-Yves Dietrich; Paul R Walker
Journal:  PLoS One       Date:  2016-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.